These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 6607323)

  • 21. [Treatment of hematological malignancies with recombinant leukocyte A interferon (rIFN-alpha A)].
    Ohno R; Kodera Y; Ogura M; Murase T; Emi N; Okumura M; Morishita Y; Nagura E; Minami S; Morishima Y
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2531-6. PubMed ID: 6594973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
    Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
    Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
    Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
    In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
    Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K
    Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
    Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
    J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
    Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
    Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
    Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel R
    Cancer Treat Rep; 1986 Apr; 70(4):473-6. PubMed ID: 3698041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.
    Tamura T; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Fujiwara Y; Nakagawa K; Minato K; Bungo M; Saijo N
    Cancer Res; 1989 Feb; 49(3):730-5. PubMed ID: 2783385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
    O'Brien S; Kantarjian H; Beran M; Robertson LE; Koller C; Lerner S; Keating MJ
    Blood; 1995 Aug; 86(4):1298-300. PubMed ID: 7632936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma.
    Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Israel L; Falcoff E; Schwab D; Pouillart P
    Cancer; 1986 Jul; 58(2):215-8. PubMed ID: 3719515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
    Bain VG; Kaita KD; Yoshida EM; Swain MG; Heathcote EJ; Neumann AU; Fiscella M; Yu R; Osborn BL; Cronin PW; Freimuth WW; McHutchison JG; Subramanian GM
    J Hepatol; 2006 Apr; 44(4):671-8. PubMed ID: 16487617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.
    Robertson MJ; Pelloso D; Abonour R; Hromas RA; Nelson RP; Wood L; Cornetta K
    Clin Cancer Res; 2002 Nov; 8(11):3383-93. PubMed ID: 12429625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human alpha-lymphoblastoid interferon. A phase I study including pharmacokinetics and effects on hematologic stem cells (CFU-GMs).
    Sarna G; Figlin R; Bryson Y; Garratty E; Myers L; Le Fevre C; Mauritzon N; Cline M
    Am J Clin Oncol; 1985 Oct; 8(5):406-12. PubMed ID: 4061375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
    Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
    Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of multiple myeloma with recombinant human leukocyte A interferon.
    Ohno R; Kimura K; Amaki I; Imamura Y; Masaoka T; Miyazaki T; Yoshida Y; Miura Y; Maekawa T; Oguro M
    Cancer Treat Rep; 1985 Dec; 69(12):1433-5. PubMed ID: 4075317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
    Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I-II trial on natural beta interferon in chemoresistant and relapsing multiple myeloma.
    Liberati AM; Cinieri S; Senatore MG; Portuesi MG; De Angelis V; Di Clemente F; Schippa M; Ferrajoli A; Arzano S; Berruto P
    Haematologica; 1990; 75(5):436-42. PubMed ID: 2129033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.